ECSP24032906A - Compuestos y métodos dirigidos a la interleucina-34 - Google Patents

Compuestos y métodos dirigidos a la interleucina-34

Info

Publication number
ECSP24032906A
ECSP24032906A ECSENADI202432906A ECDI202432906A ECSP24032906A EC SP24032906 A ECSP24032906 A EC SP24032906A EC SENADI202432906 A ECSENADI202432906 A EC SENADI202432906A EC DI202432906 A ECDI202432906 A EC DI202432906A EC SP24032906 A ECSP24032906 A EC SP24032906A
Authority
EC
Ecuador
Prior art keywords
methods
targetting
interleukin
compounds
antibodies
Prior art date
Application number
ECSENADI202432906A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP24032906A publication Critical patent/ECSP24032906A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se relaciona con anticuerpos IL-34, composiciones que comprenden los mismos y métodos para usar los anticuerpos y/o las composiciones de estos para tratar enfermedades mediadas por el sistema inmunitario tales como enfermedades neurodegenerativas, por ejemplo, la enfermedad de Alzheimer o una enfermedad de tauopatía.
ECSENADI202432906A 2021-10-29 2024-04-29 Compuestos y métodos dirigidos a la interleucina-34 ECSP24032906A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163273216P 2021-10-29 2021-10-29

Publications (1)

Publication Number Publication Date
ECSP24032906A true ECSP24032906A (es) 2024-05-31

Family

ID=84367272

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202432906A ECSP24032906A (es) 2021-10-29 2024-04-29 Compuestos y métodos dirigidos a la interleucina-34

Country Status (19)

Country Link
US (2) US11976114B2 (es)
EP (1) EP4423127A1 (es)
JP (3) JP7622019B2 (es)
KR (1) KR20240099349A (es)
CN (1) CN118475610A (es)
AR (1) AR127484A1 (es)
AU (1) AU2022376940A1 (es)
CA (1) CA3236555A1 (es)
CL (1) CL2024001303A1 (es)
CO (1) CO2024005417A2 (es)
CR (1) CR20240170A (es)
DO (1) DOP2024000076A (es)
EC (1) ECSP24032906A (es)
IL (1) IL312380A (es)
JO (1) JOP20240103A1 (es)
MX (1) MX2024005153A (es)
PE (1) PE20241471A1 (es)
TW (1) TW202336034A (es)
WO (1) WO2023076995A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3243602A1 (en) * 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101706789B1 (ko) 2008-07-21 2017-02-14 프로비오드룩 아게 진단용 항체 검사법
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
WO2012019061A2 (en) * 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
SI3339323T1 (sl) 2010-08-12 2019-12-31 Eli Lilly And Company Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
EP3174895A1 (en) 2014-07-28 2017-06-07 Nogra Pharma Limited Methods and compositions for diagnosing and treating inflammatory bowel disorders
ES2870983T3 (es) 2014-12-19 2021-10-28 Univ Nantes Anticuerpos anti-IL-34
HUE057285T2 (hu) * 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
HK1249016A1 (zh) 2015-06-02 2018-10-26 豪夫迈‧罗氏有限公司 使用抗il-34抗体治疗神经疾病的组合物和方法
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
JP6949102B2 (ja) 2016-08-09 2021-10-13 イーライ リリー アンド カンパニー 併用療法
TWI789644B (zh) 2017-04-20 2023-01-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
EP3758736B1 (en) 2018-03-02 2024-05-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Il-34 for use in a method of treating retinal inflammation and neurodegeneration
KR102905634B1 (ko) 2019-05-31 2025-12-30 일라이 릴리 앤드 캄파니 인간 타우를 표적화하는 화합물 및 방법
AR121898A1 (es) 2020-04-30 2022-07-20 Lilly Co Eli Compuestos y métodos dirigidos a interleucina-34

Also Published As

Publication number Publication date
KR20240099349A (ko) 2024-06-28
CR20240170A (es) 2024-05-24
JP2023067832A (ja) 2023-05-16
US20230279094A1 (en) 2023-09-07
WO2023076995A1 (en) 2023-05-04
EP4423127A1 (en) 2024-09-04
JP2025063187A (ja) 2025-04-15
JOP20240103A1 (ar) 2024-04-29
CL2024001303A1 (es) 2024-08-30
IL312380A (en) 2024-06-01
CA3236555A1 (en) 2023-05-04
DOP2024000076A (es) 2024-06-16
CN118475610A (zh) 2024-08-09
TW202336034A (zh) 2023-09-16
CO2024005417A2 (es) 2024-05-30
US11976114B2 (en) 2024-05-07
JP7622019B2 (ja) 2025-01-27
PE20241471A1 (es) 2024-07-17
MX2024005153A (es) 2024-05-13
JP2024091777A (ja) 2024-07-05
AR127484A1 (es) 2024-01-31
AU2022376940A1 (en) 2024-05-02
US20240309082A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
ECSP22084245A (es) Compuestos y métodos dirigidos a interleucina-34
AR132340A1 (es) Compuestos tricíclicos para el tratamiento de cáncer
DOP2021000229A (es) Materiales y métodos para modular la inmunidad mediada por cédula t
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
CO2022013274A2 (es) Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
ECSP20075198A (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anti-cd33/anti-cd3 y usos de estos
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
CL2019003049A1 (es) Compuestos de heteroarilo bicíclicos 6-6 fusionados y su uso como inhibidores de lats.
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
UY38476A (es) Inhibidores de arg1 y/o arg2
BR112018067775A2 (pt) inibidores de mcl-1 indol substituído
CL2019001891A1 (es) Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas.
CO6670589A2 (es) Compuestos para reducir la producción de beta-amiloide
UY39011A (es) Métodos para purificar cannabinoides, composiciones y kits de estos
CL2023002966A1 (es) Compuestos de oxoisoindolina sustituidos con piridinilo
GT200400076A (es) Ligandos de receptores de cannabinoides y sus usos
PA8601001A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
BR0314611A (pt) Compostos de tiazol para o tratamento de distúrbios neurodegenerativos
MX2019002438A (es) Compuestos triciclicos fusionados de piridazinona utiles para tratar infecciones de orthomyxovirus.
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
GEAP202516611A (en) Nlrp3 modulators
DOP2024000076A (es) Compuestos y métodos dirigidos a la interleucina-34
MX2019013524A (es) Composiciones para tratar enfermedades neurodegenerativas.